Valeant gets an FDA OK for new pso­ri­a­sis drug bro­dalum­ab — but there’s a big catch

The FDA has come through with an ap­proval for Valeant’s pso­ri­a­sis drug bro­dalum­ab. But they’ve hob­bled it with a black box safe­ty warn­ing on sui­ci­dal ideation and a risk mit­i­ga­tion mar­ket­ing pro­gram that will like­ly hob­ble its rev­enue in an in­tense­ly com­pet­i­tive mar­ket.

An FDA pan­el al­ready flagged through the drug — to be sold as Siliq — with many of the ex­perts clear­ly more in­ter­est­ed in ob­tain­ing an­oth­er ar­row for their quiver rather than the po­ten­tial safe­ty is­sues, which they felt were man­age­able.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER